News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
816,271 Results
Type
Article (74377)
Company Profile (644)
Press Release (741250)
Multimedia
Podcasts (124)
Webinars (14)
Section
Business (227273)
Career Advice (3720)
Deals (39270)
Drug Delivery (129)
Drug Development (89284)
Employer Resources (198)
FDA (17840)
Job Trends (17131)
News (387416)
Policy (38742)
Tag
Academia (2999)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (94)
Alliances (55915)
ALS (99)
Alzheimer's disease (1501)
Antibody-drug conjugate (ADC) (156)
Approvals (17806)
Artificial intelligence (299)
Autoimmune disease (28)
Automation (16)
Bankruptcy (403)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (440)
Bladder cancer (84)
Brain cancer (32)
Breast cancer (301)
Cancer (2423)
Cardiovascular disease (203)
Career advice (3169)
Career pathing (34)
CAR-T (172)
Cell therapy (479)
Cervical cancer (21)
Clinical research (72119)
Collaboration (910)
Compensation (543)
Complete response letters (30)
COVID-19 (2866)
CRISPR (48)
C-suite (264)
Cystic fibrosis (107)
Data (2257)
Decentralized trials (2)
Denatured (42)
Depression (54)
Diabetes (297)
Diagnostics (6913)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (132)
Drug pricing (126)
Drug shortages (33)
Duchenne muscular dystrophy (101)
Earnings (93771)
Editorial (44)
Employer branding (25)
Employer resources (167)
Events (128818)
Executive appointments (773)
FDA (19154)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (807)
Gene editing (119)
Generative AI (28)
Gene therapy (354)
GLP-1 (850)
Government (5107)
Grass and pollen (6)
Guidances (59)
Healthcare (20869)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (146)
Indications (30)
Infectious disease (3026)
Inflammatory bowel disease (152)
Inflation Reduction Act (11)
Influenza (56)
Intellectual property (101)
Interviews (726)
IPO (17738)
IRA (51)
Job creations (4986)
Job search strategy (2593)
Kidney cancer (11)
Labor market (42)
Layoffs (553)
Leadership (24)
Legal (9910)
Liver cancer (81)
Lung cancer (345)
Lymphoma (158)
Machine learning (7)
Management (65)
Manufacturing (343)
MASH (74)
Medical device (14616)
Medtech (14621)
Mergers & acquisitions (22073)
Metabolic disorders (785)
Multiple sclerosis (87)
NASH (23)
Neurodegenerative disease (113)
Neuropsychiatric disorders (34)
Neuroscience (2101)
NextGen: Class of 2025 (7635)
Non-profit (5080)
Now hiring (40)
Obesity (423)
Opinion (275)
Ovarian cancer (78)
Pain (97)
Pancreatic cancer (86)
Parkinson's disease (160)
Partnered (22)
Patents (250)
Patient recruitment (114)
Peanut (51)
People (64039)
Pharmaceutical (133)
Pharmacy benefit managers (21)
Phase I (22298)
Phase II (31454)
Phase III (23718)
Pipeline (1236)
Policy (170)
Postmarket research (3254)
Preclinical (9843)
Press Release (72)
Prostate cancer (113)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (429)
Real estate (7136)
Recruiting (75)
Regulatory (26033)
Reports (57)
Research institute (2655)
Resumes & cover letters (579)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (80)
Series A (142)
Series B (91)
Service/supplier (26)
Sickle cell disease (58)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4195)
State (2)
Stomach cancer (16)
Supply chain (75)
Tariffs (45)
The Weekly (80)
Vaccines (809)
Venture capitalists (44)
Weight loss (304)
Women's health (38)
Worklife (20)
Date
Today (183)
Last 7 days (921)
Last 30 days (2824)
Last 365 days (35388)
2025 (11431)
2024 (37898)
2023 (42567)
2022 (53926)
2021 (58723)
2020 (57663)
2019 (51302)
2018 (39084)
2017 (36829)
2016 (37734)
2015 (43725)
2014 (38362)
2013 (34352)
2012 (36247)
2011 (36361)
2010 (35764)
Location
Africa (1190)
Alabama (60)
Alaska (7)
Arizona (247)
Arkansas (14)
Asia (48428)
Australia (8315)
California (6403)
Canada (2053)
China (559)
Colorado (283)
Connecticut (299)
Delaware (156)
Europe (109713)
Florida (937)
Georgia (219)
Hawaii (1)
Idaho (63)
Illinois (611)
India (30)
Indiana (330)
Iowa (12)
Japan (167)
Kansas (110)
Kentucky (27)
Louisiana (14)
Maine (70)
Maryland (961)
Massachusetts (4921)
Michigan (245)
Minnesota (419)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (65)
New Hampshire (69)
New Jersey (1814)
New Mexico (31)
New York (1814)
North Carolina (1120)
North Dakota (9)
Northern California (2736)
Ohio (218)
Oklahoma (15)
Oregon (46)
Pennsylvania (1415)
Puerto Rico (13)
Rhode Island (36)
South America (1562)
South Carolina (23)
South Dakota (1)
Southern California (2370)
Tennessee (104)
Texas (954)
United States (24576)
Utah (191)
Virginia (168)
Washington D.C. (69)
Washington State (600)
West Virginia (3)
Wisconsin (67)
816,271 Results for "torii pharmaceutical co".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Press Releases
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
December 9, 2024
·
5 min read
Drug Development
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
Verrica Pharmaceuticals Inc. announced that its development and commercialization partner, Torii Pharmaceutical Co., Ltd., reported positive top-line results from its Phase 3 trial of TO-208 for the treatment of Molluscum Contagiosum in Japan.
December 15, 2023
·
4 min read
Drug Development
Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Torii Pharmaceutical Co., Ltd. (“Torii”) dosed the first patient in its Phase 3 trial of VP-102.
August 1, 2022
·
4 min read
Business
Nogra Pharma announces out-licensing agreement with Torii Pharmaceutical for Japan for New Chemical Entity topical acne treatment
Nogra Pharma today announces it has entered into an out-licensing agreement with Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551), to further develop and commercialise NAC-GED-0507 in Japan for the treatment of acne vulgaris.
January 26, 2023
·
5 min read
Biotech Bay
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
NovaBay® Pharmaceuticals, Inc. and Eyenovia, Inc. have commenced activities under a previously announced co-promotion agreement.
July 1, 2024
·
8 min read
Press Releases
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
April 29, 2025
·
1 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Press Releases
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine
April 28, 2025
·
3 min read
Press Releases
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
April 23, 2025
·
3 min read
1 of 81,628
Next
